Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-9 of 9 for your search:
Cancer Type:
Skin cancer, Kaposi sarcoma
Stage/Subtype of Cancer:
recurrent Kaposi sarcoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
AMC-059
, AMC-059, PTC299-ONC-005-KS, NCT00686842
2.
Sunitinib in Soft Tissue Sarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
Sunitinib in Sarcoma
, AAAC2308, NCT00859456
3.
Doxorubicin Hydrochloride Liposome and Bevacizumab Followed by Bevacizumab Alone in Treating Patients With Advanced Kaposi Sarcoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-09-C-0130
, 09-C-0130, NCI-P09493, GENENTECH-NCI-09-C-0130
4.
Sorafenib in Treating Patients With Kaposi's Sarcoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0083
, 7048, NCI-7048, NCI-P6700, NCT00304122
5.
Dose Evaluation Study Of Oral Eltrombopag In Patients With Sarcoma Receiving The Adriamycin And Ifosfamide Regimen
Phase:
Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TRC105499
, NCT00358540
6.
1-methyl-d-tryptophan in Treating Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
VU-VICC-PHI-0814
, VICCPHI0814, NLGC-NLG-2100, IRB#080257, VICTR-1855, NCT00788086
7.
Antiretroviral Therapy With or Without Bortezomib or Combination Chemotherapy and Rituximab or Sirolimus Only or Observation Only in Treating Patients With Castleman's Disease
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
12 and over
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0275
, NCT00099073
8.
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
AMC-051
, AMC-051, WYETH-0468X-4420, NCT00450320
9.
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
JHOC-J0685
, NA_00003073, J0685, NCT00499733
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute